NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50268-0426-12 | 50268-0426 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 24, 2017 | In Use | |
58468-7820-03 | 58468-7820 | Vandetanib | Caprelsa | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | Jul 25, 2011 | In Use | |
72606-0556-01 | 72606-0556 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
59651-0531-10 | 59651-0531 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
60505-0134-00 | 60505-0134 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | May 29, 2002 | In Use | |
68084-0921-95 | 68084-0921 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Feb 26, 2015 | In Use | |
65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
00143-9606-01 | 00143-9606 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jun 8, 2020 | In Use | |
00172-7312-00 | 00172-7312 | Cyclosporine Modified | Cyclosporine Modified | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Mar 29, 2005 | Mar 31, 2017 | No Longer Used |
16729-0306-10 | 16729-0306 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 9, 2019 | In Use | |
16729-0050-53 | 16729-0050 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
47335-0472-83 | 47335-0472 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
59923-0707-05 | 59923-0707 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
60505-3631-03 | 60505-3631 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
00069-0188-21 | 00069-0188 | Palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb 3, 2015 | In Use | |
50242-0210-12 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sep 28, 2022 | In Use | |
81864-0103-30 | 81864-0103 | Momelotinib | Ojjaara | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sep 15, 2023 | In Use | |
71332-0006-12 | 71332-0006 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jun 24, 2024 | In Use | |
64144-0503-02 | 64144-0503 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 13, 2016 | In Use | |
00074-0576-30 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Jun 15, 2022 | In Use | |
62332-0566-90 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
47335-0472-81 | 47335-0472 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
68083-0503-01 | 68083-0503 | Thiotepa | Thiotepa | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Jan 3, 2022 | In Use | |
82950-0001-20 | 82950-0001 | TOVORAFENIB | OJEMDA | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Oral | Apr 30, 2024 | In Use | |
43598-0603-30 | 43598-0603 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use |
Found 11465 results — Export these results